Sanofi: Q3 2015 Results (Sanofi) - Oct 30, 2015 - “Sanofi has decided not to pursue development of vatelizumab, following the results of a Phase II pre-planned interim analysis in Multiple Sclerosis that revealed the primary efficacy endpoint was not met”
Discontinued • Multiple Sclerosis
|